StemCell Therapy

Mr. Deven Patel President, CEO and Co-founder

Mr. Deven Patel is the President, CEO and Cofounder of GIOSTAR. He has also served as the CEO, President and Board of Directors in highly comprehensive environment of Healthcare Management, Architectural, General Construction, Alternative Energy and multifaceted Internet industries. Apart from serving as CEO and President, Mr. Patel has also served in a key positions of several public and private organizations such as Asian & Pacific American Coalition, Asian Outreach Committee Children Memorial Hospital San Diego, Federation of India Associations, National Federation of Indian American Association, CRY America, Global Organization of People of Indian Origin, Kelly Dean Citizens Awareness Circle, Phillip Redmond Foundation, Lockport Planning Commission.

During his early career, Mr. Patel was involved with the design and construction of several healthcare projects as an architect and a builder. He has also served as a partner for an assisted living and wellness center fostering care for senior citizens suffering from special conditions.

Dr. Anand Srivastava, M.S., Ph.D. Chairman, Cofounder and Chief Scientific Officer

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals.

Dr. Anand Srivastava's success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastava's wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastava's research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and he has been cited extensively by other scientists. Dr. Anand Srivastava's expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the "Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in "WHO IS WHO IN AMERICA" data bank two times, first in 2005 and second in 2010.

Dr. Anand Srivastava's Long Profile

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals.

Dr. Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Companys primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

Giostar is worlds leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a world-renowned authority in the field of Stem cell biology, Cancer, Gene therapy. Several governments including USA, India, China, Turkey, Kuwait, Thailand and many others seek his advice and guidance on drafting their strategic & national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership a group of esteemed scientists and clinicians have developed and established Stem cell therapy for various types of Autoimmune diseases and blood disorders which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe. Giostar is already the official collaborator of Government of Gujarat, India by setting up a state of art stem cell treatment hospital in Surat civil hospital for the less fortunate tribal populace of the southern belt of Gujarat suffering from Sickle Cell Anemia. Several state Governments in India is looking for a collaborative efforts of GIOSTAR and Dr. Anand to develop stem cell transplant program in their respective states.

SUMMARY OF DR. SRIVASTAVAS WORK:

Dr. Anand Srivastavas success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastavas wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastavas research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and he has been cited extensively by other scientists. Dr. Anand Srivastavas expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in WHO IS WHO IN AMERICA data bank two times, first in 2005 and second in 2010.

POSITIONS HELD BY DR. SRIVASTAVA (1997 to Date):

1. Chairman & Cofounder (2008-till date): Global Institute of Stem Cell Therapy and Research, San Diego, CA. USA. 2. Associate Professor: Department of Cellular and Molecular Biology, School of Medicine, University of California Los Angeles (UCLA), CA, USA. 3. Visiting Senior Scientist: Department of Stem Cell Biology, Burnham Research Institute for Medical Science, San Diego, CA, USA. 4. Senior Scientist: Stem Cell Core Facility, The Salk Research Institute, La Jolla, CA, USA. 5. Associate Professor: Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA. 6. Assistant Professor: Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA 7. Honorary Visiting Professor: National Research Institute, Nansei, Mie, JAPAN.

SPECIAL STEM ISSUES OF JOURNALS DEVOTED TO DR. SRIVASTAVA

1. Current Topics of Medicinal Chemistry among top five medicinal chemistry journal devoted its special issue of stem cell to Dr. Srivastava in 2010. 2. Stem Cell International devoted its special issue on stem cells to Dr. Srivastava in 2012.

EXPERT SCIENTIFIC REVIEWER FOR LEADING JOURNALS OF MEDICINE:

Dr. Srivastava is the member of the several scientific review committees and reviewing the research grants. He has written several review articles and scientific manuscripts. He is also the reviewer and editor of several scientific journals.

1. Advances in Stem Cells 2. Current pharmaceutical Design 3. Current Topics in Medicinal Chemistry 4. Stem Cells 5. Stem Cell International 6. Current in Cell Medicine 7. Journal of Stem Cell Research and Therapy 8. Conference Papers in Molecular Biology 9. Journal of Pharmaceutics 10. Current Pharmaceutical Biotechnology 11. Open Journal of Organ Transplant Surgery 12. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 13. Stem Cells and Cloning: Advances and Applications 14. Blood and Lymphatic Cancer: Targets and Therapy 15. Degenerative Neurological and Neuromuscular Disease 16. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 17. Immuno Targets and Therapy 18. Current Vascular Pharmacology 19. Gastrointestinal Cancer: Targets and Therapy 20. Journal of Bioengineering and Biomedical Sciences 21. The Application of Clinical Genetics 22. Journal of Tissue Science & Engineering 23. Neuropsychiatric Disease and Treatment 24. Current Tissue Engineering 25. Hepatic Medicine: Evidence and Research 26. Current Drug Discovery Technologies 27. Current Bioactive Compounds 28. Transplant Research and Risk Management 29. Biosimilars 30. Current Drug Delivery 31. Journal of Experimental Pharmacology 32. Open Journal of Regenerative Medicine 33. Current Diabetes Reviews 34. Journal of Fertilization: In Vitro 35. Clinical and Translational Medicine

FELLOWSHIPS/ AWARDS:

2003 Awarded with NIMA (National Integrated Medical Association) Outstanding Scientist award from NIMA, India. 2003 Awarded with Excellent Scientist Award from Bharat Vikas Parisad, India for continuous excellent performance in the life science research. The 18th International Congress of Clinical Chemistry and Laboratory Medicine Kyoto Excellent Poster Award, Kyoto, Japan. 2002 Best Scientist Award for excellent contribution in the field of life science research from Kayastha Maha Sabha, Varanasi, India. 1998-2000: Long-term STA/JISTEC Award (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship award for two year from government of Japan. 1997-1998: Short-term STA/JISTEC Award (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship Award for three months from government of Japan (October 1997- January 1998). 1997-1998: Awarded with Research Associate-ship award from CSIR (Council of Scientific and Industrial Research) Government of India. 1990-1995: CAS (Center of Advanced Study) Award in Zoology. A doctoral research fellowship award from Government of India.

THE FOLLOWING SUMMARIZES DR. SRIVASTAVAS MAJOR SCIENTIFIC ACHIEVEMENTS:

1. Dr. Srivastava developed the animal material free and serum free Human embryonic Stem cell culture condition to use the Human ES cells to treat the human diseases. 2. Dr. Srivastava for the first time showed that if the ES cell injected into developing fetuses in utero takes participation in development of all body of a living organism. 3. For the first time he showed that ES cell is better accepted by the transplanted animals in comparison to adult stem cells. 4. For the first time he showed the way to generate the high number of pre-erythrocytes using glucocorticoid hormone. Which may be use to treat several blood diseases. 5. For the first time Using ES cells he generated the high number of CD34+ expressing a kind of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune reconstitution and blood diseases. 6. For the first time he showed the molecular mechanism behind the regulation of ES cell differentiation into hematopoietic cells. 7. For the first time he showed that ES cells automatically recognize the damage portion of the brain and can be used to repair the damage brain. 8. For the first time he showed that ES cell can be used to treat the Crohns disease a kind of colon cancer. 9. For the first time, he demonstrated that the mammalian fetuses can be programmed inside the mother uterus to face the challenges of the future possible infection. This finding is very important to develop the advanced therapy for any fatal disease such as cancer and AIDS. Utilizing these techniques, fetuses can be given information about all possible infections and the capability to counter those infections and disease. 10. He has demonstrated for the first time that it is easy to correct the genetic diseases in developing fetus in utero in comparison to adult animals. 11. He has shown for the first time that the lung cancer cells can be treated with the help of plant product curcumin and can be used as effective cancer therapeutic agent. He also demonstrated that how curcumin regulated the genes related to programmed death of cancerous cell. Finding help in development of non-toxic, less expensive, easily available drug for cancer. 12. The biggest problem in the treatment of cancer and other diseases is the non-specific distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava for the first time developed a technique that can help in targeting the diseased tissues using the tissue receptor binding peptide ligands. These techniques can be used for targeted delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the mother uterus without harming the normal tissues of mother and fetus. 13. For the first time, He demonstrated the insertion of foreign pancreas enzyme specific gene promoter into the developing animals embryo and successfully shown the incorporation and regulation of pancreatic enzyme in the control of inserted gene. This is very important finding and proves that the defective genes can be replaced easily and effectively by the normal functional genes during the development of animals. This finding will help in the change of defective genes of insulin hormone, which is present in the pancreas of diabetic patients and many other genetic diseases also. 14. For the first time, He reported the gene sequence of all important pancreatic enzymes (three isoform of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three forms of carboxypeptidases and lipase) and its evolutionary relationship with human. Also,he reported first time the regulation of digestion by these enzymes in the alimentary canal during digestion of proteins in the developing animals. 15. For the first time, He cloned and sequenced two types of human homologue of Vitamin D receptor gene from Japanese flounder, which is most important receptor, which help in the development of bone. Before my report, characters of this gene were not known in Japanese flounder. This finding helped in the understanding of the genetic evolution of mammals. 16. For the first time, he cloned and sequenced the homologue of human placental protein, PP11, and mouse T cell specific, Tcl-30, in pancreas of Japanese flounder, this study suggest that these genes evolved from the fish pancreas and in fish it helps in synthesizing the digestive enzymes but during the evolution its function got changed and work differently in the mammalian placenta. This was very important finding related to this rare gene. 17. For the first time, He has shown that the Hox and sonic hedgehog genes regulate the development of bones and respiratory organs. He also demonstrated that how these genes could be regulated artificially. This was very important finding because it gives the idea that how genes regulate the development of organs. 18. For the first time, He has purified and characterized the human homolog of AAT and ASPT enzymes, which is the basic clinical marker in all the infection and major marker of liver function test. 19. For the first time, he demonstrated the co-ordination of AAT and ASPT enzymes in the production of energy through the amino acids after aerobic respiration. 20. For the first time, he has shown that according to metabolic demand of the body AAT and ASPT genes synthesized additional forms of its isoform to cope up with the extra energy demand and work as an on and off switch.

DR. SRIVASTAVAS EXCELLENCE IN SEVERAL ADVANCED BIOLOGICAL TECHNIQUES:

Techniques related to Human Embryonic Stem Cell Human Embryonic Stem cell culture, Serum free and feeder free hES cell culture, in vitro differentiation of hES cells into neural cells, in vitro differentiation of hES into hematopoietic cells and red blood cells under the control of cytokines. Gene regulation studies using RT-PCR, Real time PCR, Northern blot, Southern blot and in situ hybridization, immunohistochemistry during the differentiation, Cell cycle regulation studies during differentiation of hES cells into hematopoietic and neural cells. Use of siRNA for blocking a specific cell cycle. FACS analysis of differentiated cells and cell shorting. ES cell transfection.

In vivo studies with ES cells Created a mouse model for study the effect of ES cells on damaged brain. Injection of ES cells into mouse brain, tail vein injection, in vivo tracking of ES cell migration. Used the ES cells for repair of damaged brain. Gene and protein regulation during neural cell differentiation. Studies on transcription factors. Histochemical analysis of transplanted ES cells using fluorescent, confocal microscopy and deconvolution microscopy. Created a mouse model for Crohns disease. In vivo migration of ES cells into diseased portion of intestine. Studies on inflammatory cytokines during the repair of Crohns disease with ES cell. Gene regulation studies during this process. Elisa assays for the cytokines. Stem cell niche interaction.

Created in utero mouse model for ES cells transplantation. Used this model to make chimeric animals. Distribution and differentiation of ES cells into developing mouse embryo. FACS and magnetic shorting of ES cells derived CD31+, CD34+, CD45+ cells from the transplanted animal tissues. Gene and protein regulation of in vivo differentiating cells.

Created immunocompromised mouse model to study the effect of in vivo immune component on T7 phage virus. In vivo selection of tissue specific receptor binding peptide using in vivo biopanning method. Tissue targeted gene delivery to correct the blood related genetic diseases. Gene cloning, gene sequencing, synthesis of RNA probes. Protein and enzyme biochemistry Protein assay, peptide structure and amino acid sequencing, Enzyme assay, Ultra centrifugation, Ion exchange chromatography, column chromatography, HPLC, Protein and gene regulation during the development. Enzyme kinetics, Enzyme inhibition, SDS gel electrophoresis, Protein characterization.

Selection of cell receptor binding peptide and Phage display technology

- Selection of tissue receptor binding peptides using T7 phage display system. - In vivo and in vitro biopanning for selection of receptor binding peptides sequences. - Characterization of targeted cells and tissues using histochemistry and gene expression analyses. - In vivo delivery of drugs and genes to targeted tissues using microinjection.

Cancer Research

- Studying the role of pharmaceutical agent curcumin as an anti-lung cancer drug and develop it as a non-toxic cancer drug. - Role of apoptotic genes on the lung cancer cell lines. - Development of tissue targeted delivery protocol of pharmaceuticals agents for cancer and genetic diseases

Fluorescence techniques for nucleic acid sequence detection: Clinical and diagnostic applications

- Fluorescent labeling of DNA and RNA probes. - Fluorescence resonance energy transfer (FRET) protocols for DNA and RNA sequence. detection in real time (Sequence Detection System 7700, ABI, Perkin Elmer) - FRET protocols for monitoring ribozyme reactions and kinetics in real time (TaqMan, SDS 7700, ABI, Perkin Elmer). - Accessibility studies for DNA and RNA target sequences using FRET. - Fluorescence polarization protocols for monitoring ribozyme reactions (POLARstar, BMG, GmbH) and for DNA and RNA sequence detection. - Sequence detection with Syber green dye in real time quantitative PCR by Light Cycler (Roche Diagnostics, USA). - Single nucleotide polymorphism detection in real time with LightCycler hybridization probes (Roche Diagnostics, USA).

Gene detection technology: Research and Clinical applications

- Preparation of radio labeled & fluorescent labeled RNAs (ribozymes and target substrates). - In vitro transcription of RNA. - Expression of ribozymes in yeast. - Isolation and purification of cellular RNA. - RNase Protection Assay. - Kinetic characterization of ribozymes & binding kinetics using fluorescence methods. - Designing, synthesis and characterization of allosteric ribozymes induced by small drug ligands (such as theophylline & caffeine).

In utero transplantation: Clinical Research to cure the fetal genetic diseases

- Developed in utero microinjection techniques to transplant the bone marrow and stem cells to cure blood related genetic disease. - Harvest the fetal liver, bone marrow and mouse embryonic stem cells for transplantation. - Culture mouse embryonic stem cell and in vitro differentiation into the blood cells. - Fractionation of cells using flow cytometry techniques.

Standard Molecular biology techniques - Standard and site directed mutagenesis polymerase chain reaction (PCR). - Preparation and purification of plasmids. - Transformations and Transfection of DNA. - Cloning of DNA. - Solid phase synthesis of DNA (Gene Assembler, Pharmacia). - DNA sequencing & fragment analyses (ABI 310 Gene Sequencer, Perkin Elmer). - Quantitation of DNA, RNA and proteins. - Mammalian cell culture and yeast culture. - Gel electrophoresis (polyacrylamide and agarose). - Capillary gel electrophoresis (ABI 310 Gene Sequencer, Perkin Elmer). - Column/ gel/ thin layer chromatography. - Autoradiography by phosphorimager (Storm, Molecular Dynamics, USA). - High Performance Liquid Chromatography (HPLC). - Preparation and purification of chemical reagents & solvents. - Enzyme/ Protein/ purification and characterization. - Isolation of Genomic DNA, Genomic library Construction. - Radioimmunoassay.

General molecular and biochemical techniques

mRNA preparation and purification, Primer designing, Real-time PCR, RT-PCR, DNA cloning, DNA sequencing, Isolation of Genomic DNA, Genomic library Construction, Transformation, Transfection, Cell culture, Plasmid purification, RNA probe making, Different kinds of microscopy, In situ hybridization, Southern blotting, Northern blotting, Western blotting, Spectrophotometery, In utero-microinjection, Column chromatography, HPLC, PAGE, Agarose gel-electrophoresis, Enzyme assay, Protein assay, Enzyme/ Protein/ DNA purification, Histology, Phage display for tissue targeting, Radio-immunoassay,

INVITED SPEAKER AND PRESENTATIONS OF DR. SRIVASTAVAS SCIENTIFIC FINDINGS IN NATIONAL AND INTERNATIONAL CONFERENCES:

1. Srivastava A.S. Invited Speaker, STEM 2013, 9 Th Annual Conference on Biotechnology - Focusing On Latest Trend in Stem Cells, Regenerative Medicine and Tissue Engineering Mumbai, India, January 2013.

2. Srivastava A.S. "International Conference on Regenerative and Functional Medicine" (Regenerative Medicine-2012), San Antonio, USA. November 2012.

3. Sriavstava A.S. 2nd International Congress on Neurology & Epidemiology; "Impact of drugs on the natural history of neurological diseases". Nice, France. November 2012.

4. Srivastava A.S. Invited Speaker, International Expo and Conference on Analytrix & HPLC, Chicago, USA. October 2012.

5. Srivastava A.S. Invited Speaker at "International Conference on Emerging Cell Therapies" (Cell Therapy-2012) Chicago, USA. October 2012.

6. Srivastava A.S. Invited Speaker, 6th Neurodegenerative Conditions Research and Development Conference San Francisco, CA, USA. September 2012.

7. Srivastava A.S. 8th International Congress on Mental Dysfunction & Other Non-Motor Features In Parkinson's Disease and Related Disorders, Berlin, Germany. May 2012.

8. Srivastava A.S. International Conference and Exhibition on Neurology & Therapeutics Las Vegas, USA. May 2012.

9. Srivastava A.S. Montreal International Biotechnology Forum, Montreal, Quebec, Canada. May 2012.

10. Srivastava A.S. Invited Speaker, International Association of Neurorestoratology (IANR) V and 9th Global College Neuroprotection and Neuroregeneration (GCNN) conference with the 4th International Spinal Cord Injury Treatment & Trial Symposium (ISCITT) Xian City, China. May 2012.

11. Srivastava A.S. International Forum on the Mediterranean Diet, Ravello - Amalfi Coast, Italy. March 2012

12. Srivastava A.S. Hong Kong international Stem Cell Forum 2012, Hong Kong. February 2012.

13. Srivastava A.S. 4th International Conference on Drug Discovery and Therapy" (4th ICDDT 2012) Dubai, UAE, February 2012.

14. Srivastava A.S. Evolving Strategies in Hematopoietic Stem Cell Transplantation- San Diego, USA. February 2012.

15. Srivastava A.S. Hebei International Biotechnology Forum; Shijiazhuang, Hebei, China. November 2011

16. Srivastava A.S. 3rd International Conference on Drug Discovery and Therapy. Regenerative Medicine. Dubai, UAE. February 2011.

17. Srivastava A.S. 3rd Annual Congress of Regenerative Medicine & Stem Cell-2010, Shanghai, China. December 2010.

18. Srivastava A.S. 1st Annual Tetra-Congress of MolMed-Personal Medicine Congress 2010, Shanghai, China. November 2010.

19. Srivastava A.S. International Association of Neurorestoratology(IANR), American Journal of Neuroprotection and Neuroregeneration, Beijing, China. October 2010.

20. Srivastava A.S. EPS Global International Neuroscience Forum. Nha Trang, Vietnam. October 2010.

21. Srivastava A.S. EPS Global International Neuroscience Forum, Guangzhou, China. September 2010.

22. Srivastava A.S. 4th Academic Congress of International Chinese Neurosurgical Sciences. Chengdu, China. June 2010.

23. Srivastava A.S. 1st Annual World Congress of Immunodiseases and Therapy (WCIT 2010). Beijing, China. May 2010.

24. Srivastava A.S. 3rd PepCon-2010 - Protein Misfolding and Neurodegeneration. Beijing, China. March 2010

25. Srivastava A.S. Potential use of ES cells in hematopoietic and neural diseases. City of Hope National Medical Center, Duarte, California, USA. January, 2009.

26. Srivastava A.S. Differentiation of Human Embryonic Stem cell into erythrocyte and neural precursor cells: Its potential application. Cleveland Clinic, Cleveland, Ohio, USA, December, 2008.

27. Srivastava A.S. Potential of ES cell in repair of Hematopoietic and neural diseases. International Conference in Stem cell, Kerala, India, August, 2008.

28. Srivastava A. S., Singh U. and Carrier E. Embryonic stem cell improve colitis and decrease IL- 12 levels in the colitis mice. BMRP Fourth Annual Investigator Meeting, Los Angeles, USA. 2006

29. Carrier E., Shermila Kausal and Srivastava A. S. Gene Regulation During the Erythrocytic Differentiation of Embryonic Stem Cells. Blood (ASH Meeting), 2005.

30. Carrier E., Shermila Kausal and Srivastava A. S. Differentiation of Human ES cell into the Hemangioblast. Blood (AHS Meeting), 2005.

31. Srivastava A.S., Zhongling F., Victor A., Kim H.S. and Carrier E. Repair of Crohns disease with embryonic stem cells. Broad Medical Research Program, Third Annual Investigator Meeting, Los Angeles, CA, USA, 2005.

32. Srivastava A.S., Shenouda S. and Carrier E. Damaged murine brain induces ES cells into migration and proliferation. Blood:104, 779a, 2004.

33. Srivastava A.S., Shenouda S. and Carrier E. Increased expression of OCT4,SOX2 and FGF4 genes following injection of embryonic stem cell into damaged murine brain. American Society of Gene Therapy, 2004.

34. Srivastava A.S. and Carrier E.; Distribution and stability of T7 phage in mouse blood and tissues. Molecular Therapy:7, 230, 2003.

35. Moustafa M., Srivastava A.S., Nedelcu E., Minev B., Carrier E.; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. 32nd annual meeting of the international society for Experimental Hematology, 31, 274, 2003 (Paris, France).

36. Steve S., Srivastava A.S. Carrier E.; In vivo survival of hematopoietic stem cell in mouse brain.11th international symposium on recent advances in Stem cell transplantation, 89-90, 2003 (San Diego, USA).

37. Srivastava A.S., Carrier E.; Distribution and stability of T7 phage in mouse. 11th international symposium on recent advances in Stem cell transplantation, 93, 2003 (San Diego, USA).

38. Elena N., Srivastava A.S., Varki N.M., Assatourian G. and E. Carrier; Embryonic stem cells survive and proliferate after intraperitoneal In utero transplantation and produce teratocarcinomas. Blood:160b, 2002.

39. Srivastava A.S and E. Carrier; In utero targeting the fetal liver by using T7 phage display system. Blood:489b, 2002.

40. Srivastava A.S. and E. Carrier; Factor responsible for in vivo neutralization of T7 phage display vector in the blood of mice. Blood:489b, 2002.

41. Srivastava A.S. and E. Carrier; Distribution and stability of T7 phage in the mouse after intravenous administration. ICCC, Kyoto, Japan. (October 2002).

42. Srivastava A.S., T. Kaido and E. Carrier; Immunological factors that affect the in vivo fate of T7 phage in the mouse. Molecular Therapy:5, 713, 2002.

43. Srivastava A.S., E. Nedelcu and E. Carrier; Engraftment of murine embryonic stem cells after in utero transplantation. Molecular Therapy:5, 1132, 2003.

44. M. Rizzi, T. Kaido, M.Gerloni, K.Schuler, A. S. Srivastava, E.Carrier and M. Zanetti; Neonatal T cell immunity by in utero immunization. AAI 2002 annual meeting, April 20 - 24, New Orleans, Experimental Biology 2002 sponsored by 7 FASEB societies.

45. Srivastava A.S., T. Kaido and E. Carrier; Kinetics of T7 phage neutralization in the blood of normal and immunodeficient mice. Blood:407, 2001.

46. Hassan S., Jody D., Srivastava A.S., T.H. Lee, M.P. Busch, Carrier E.; Immunity without microchimerism after in utero transplantation of Hematopoietic stem cell. Blood:320, 2001.

47. Srivastava A.S., Felix Tinkov, T. Friedmann and E. Carrier; Detection of T7 phage in the fetus after Systemic administration to pregnant mice. Molecular Therapy:4, 760, 2001.

48. Pillai G.R., Srivastava A.S., Hassan S., Carrier E. Differential sensitivity of human lung cancer cell lines to curcumin. 9th Annual International Symposium on Recent Advances in Hematopoietic Stem cell Transplantation. USA. 2001.

49. Hassan S., Jody D., Srivastava A.S., Carrier E.; The role of I-E molecule on survival rate and tolerance after in utero transplantation. The 42 ASH meeting, San Francisco, USA. 2000.

50. Suzuki T., Srivastava A.S., Kurokawa T.; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, April 2 - 4, 2000, Tokyo, JAPAN.

51. Srivastava A.S., Suzuki T., Kurokawa T., Kamimoto M., Nakatsuji T.; GFP expression in pancreas of developing fish embryo under control of Carboxypeptidase A promoter. Plant and Animal Genome-VIII (PAG-VIII), Conference, San Diego, California, USA. January 9th to 12th, 2000.

52. Srivastava A.S., Suzuki T., Kurokawa T.; Molecular cloning of serine protease cDNAs from pancreas of Japanese flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, Tokyo, JAPAN. 1999.

53. Suzuki T., Srivastava A.S., Kurokawa T.; Cloning of FGFRs from Flounder embryos, and their expression during axial skeletal development. 32nd Annual Meeting of the Japanese Society of Developmental Biologists. JAPAN. 1999.

54. Suzuki T., Srivastava A.S., Kurokawa T.; Expression of Signal molecules during axial skeleton development in Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.

55. Suzuki N., Suzuki T., Srivastava A.S., Kurokawa T.; cDNA cloning and expression analysis of receptor for calcitonin and calcitonin related peptide from Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.

56. Srivastava A.S., Trigun S.K., Singh S.N.; Purification and kinetics of cytosolic aspartate aminotransferase from liver of air-breathing and non air-breathing fish. National Symposium on Comparative Physiology & Endocrinology, Raipur, INDIA. 1997.

See the article here:
Stem Cell Treatment & Cure in India | GIOSTAR

This entry was posted on August 20, 2015 at 7:41 am and is filed under Stem Cell Therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |